ClinicalTrials.gg
CompletedNCT04878133OCT-CONTACTUpdated Sep 30, 2026

OCT Guided vs COmplete Pci in patieNts With sT Segment Elevation myocArdial infarCtion and mulTivessel Disease

An interventional study of OCT - optical coherence tomography in Acute Coronary Syndrome, sponsored by A.O.U. Città della Salute e della Scienza. Completed at 6 sites in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by A.O.U. Città della Salute e della Scienza · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2021, registered May 2021).
Updated Sep 30, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
460
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.

Enrollment
46th of 85
460 · median 522
Started
2021
with 9 others
No phase
29 of 138
7 open now
Registered
98th of 138
by date
Lead sponsor
7 of 138
A.O.U. Città della Salute e della Scienza

Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 46th largest by enrollment of the 85 interventional ones that give a count, is one of 10 that started in 2021, is one of 29 with no phase, and was the 98th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Acute Coronary Syndrome with a site in Italy, or all of them as a file.
02

Study summary

STEMI patients with multivessel disease will be randomized to complete PCI versus PCI driven by high risk criteria of plaques evaluated with OCT

Read the detailed description

In patients with ST segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significally reduces the risk of cardiovascular death. How to manage in this setting non-culprit lesion in patients with multivessel disease still remain a matter of debate. Recently, the COMPLETE trial showed that complete PCI of every coronary stenosis > 70% (or 50-69% lesions with FFR \< 0.8) reduces risk of myocardial infarction (MI) and unstable angina (UA) at 3 years compared with culprit-lesion PCI [1]. Whether this findings are related to revascularization of every obstructive lesions rather than lesions with vulnerable-plaque characteristics, still remain unclear.

In high risk patients such as STEMI patients, physiopathology of coronary plaque deeply differs from stable angina, mainly due to peculiar features of plaque. STEMI lesions, when evaluated at autopsy or at intracoronary imaging, showed a pro-thrombotic pattern, with high prevalence of thin cap fibro-atheroma, plaque rupture or thrombus, and a larger amount of lipids and macrophage [2-6]. In this setting, angiography, even when combined with fractional flow reserve evaluation (which can describe more accurately the functional impact of the plaque), has intrinsic limitations because of lack of information about plaque characteristics [7,8].

Optical coherence tomography (OCT) is the latest development in intravascular coronary imaging. Similarly to intravascular ultrasound (IVUS), OCT provides cross-sectional images of the vessel. However, instead of sound, OCT employs light for tissue analysis that enables visualization of the coronary lesions with almost microscopic precision [9,10].

This tool can find high risk vulnerable plaque without angiographic or functional signs of severity, helping from misdiagnosing and under-treating these lesions, that could benefit from PCI even more than obstructive lesions without vulnerable plaque characteristics.

In an OCT substudy of the COMPLETE trial, researchers determined that half of patients had obstructive nonculprit lesions with vulnerable plaque, which could explain why complete revascularization conferred better outcomes than culprit lesion-only revascularization in the main trial. This substudy pointed out also a 20% of non-obstructive non-culprit lesions with vulnerable plaque caracteristics and up to 30% of obstructive non-culprit lesions without high risk morphology [11]. It suggest that a morphological approach to PCI in high risk patients can provide a more specific treatment compared with standard angiographic/functional approach. A correct identification of coronary plaque instability in a setting of STEMI patients could deeply impact in these patients risk of cardiovascular events, angina and re- hospitalization.

Being coronary artery disease a pandemic disease with an important impact on nations health care, a reduction in events in these patients do not impact only on patients quality of life, but on health care system resources.

Consequently, we propose a randomized controlled trial to evaluate the effective benefit of OCT guided vs complete PCI in STEMI patients with multivessels coronary artery disease.

03

Conditions studied

  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with STEMI and residual non culprit CAD

Exclusion criteria

Exclusion Criteria:

  1. Refusal or inability to provide .
  2. \< 18 years of age
  3. Cardiogenic shock
  4. Previous Coronary Artery Bypass Grafting (CABG
  5. Indication for revascularization by CABG.
  6. \< 30 ml/min/m2
  7. ULM stenosis
  8. Estimated \< 3 year
  9. Non culprit CTO lesion
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
460 participants (actual)

Study arms

  • Experimental
    Exsperimental Arm

    Diagnostic Test: OCT - optical coherence tomography

  • No intervention
    Control Arm

Interventions

  • Diagnostic testOCT - optical coherence tomography

    The principle by which OCT works is similar to ultrasound, although light waves close to infrared are used instead of ultrasounds. In practice, the light waves, emitted into the vessel through a special catheter positioned in the coronary artery, meet the surrounding structures and are partly absorbed and partly reflected by them. The reflected waves are picked up by a sensor positioned on the catheter and analyzed through software that produces images visible live on a special console.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular events (MACE)

    Composite endopoint of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization.

    Time frame: 24 mounth after the recruitment in the study

Secondary outcomes

  1. Secondary efficacy end-points

    Rate of all cause mortality, cardiovascular mortality, non-fatal myocardial infarction, unplanned revascularization taking separately.

    Time frame: 24 mounth after the recruitment in the study

Other outcomes

  1. Safety end-points

    Rate of Acute kidney injury (AKI) following OCT vs complete guided PCI, defined according to the Acute Kidney Injury Network criteria

    Time frame: 24 mounth after the recruitment in the study

  2. Safety end-points

    Rate of procedural complications following each PCI: periprocedural MI defined according to the Fourth Universal Definition of Myocardial Infarction \[15\], arterial access site complications, AKI

    Time frame: 24 mounth after the recruitment in the study

07

Study locations

6 sites
  • Ospedale di Rivoli
    Rivoli, Italy 10098, Italy
  • AOU Città della Salute e della Scienza di Torino
    Torino, Italy 10126, Italy
  • Ospedale San Giovanni Bosco
    Torino, Italy 10144, Italy
  • Città della Salute e della Scienza di Torino
    Turin, Piedmont 10100, Italy
  • Citta della Salute
    Turin, Turin 10128, Italy
  • Ospedale San Luigi Gonzaga, Orbassano
    Orbassano, 10043, Italy
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Jan 2025, 47 months.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's 47 months is above that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jan 2023 → Jan 2025 and completion Jan 2025 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2021
First posted
May 7, 2021
StartActual
Feb 1, 2021
Primary completionActual
Jan 31, 2025was Jan 2023
CompletionActual
Sep 26, 2026was Jan 2025
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Sep 30, 2026
Sites
5 sites added, 5 sites removed
Show 5 added (5 Italy)
  • Ospedale di Rivoli · Rivoli, Italy
  • AOU Città della Salute e della Scienza di Torino · Torino, Italy
  • Ospedale San Giovanni Bosco · Torino, Italy
  • Città della Salute e della Scienza di Torino · Turin, Italy
  • Citta della Salute · Turin, Italy
Show 5 removed
  • Città della Salute e della Scienza di Torino · Torino, Italy
  • Ospedale di Rivoli · Rivoli, Italy
  • AOU Città della Salute e della Scienza di Torino · Torino, Italy
  • Ospedale San Giovanni Bosco · Torino, Italy
  • Citta della Salute · Turin, Italy
Sep 30, 2026
Primary completion
Jan 31, 2023→Jan 31, 2025 (actual)
Sep 30, 2026
Study completion
Jan 31, 2025→Sep 26, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Status unknown→Completed
    5 sites added, 5 sites removed
    Show 5 added (5 Italy)
    • Ospedale di Rivoli · Rivoli, Italy
    • AOU Città della Salute e della Scienza di Torino · Torino, Italy
    • Ospedale San Giovanni Bosco · Torino, Italy
    • Città della Salute e della Scienza di Torino · Turin, Italy
    • Citta della Salute · Turin, Italy
    Show 5 removed
    • Città della Salute e della Scienza di Torino · Torino, Italy
    • Ospedale di Rivoli · Rivoli, Italy
    • AOU Città della Salute e della Scienza di Torino · Torino, Italy
    • Ospedale San Giovanni Bosco · Torino, Italy
    • Citta della Salute · Turin, Italy
    Primary completion Jan 31, 2023→Jan 31, 2025 (now actual)
    Study completion Jan 31, 2025→Sep 26, 2026 (now actual)
    + 3 other changes: index terms, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04878133
Lead sponsor
A.O.U. Città della Salute e della Scienza
Responsible party
Fabrizio D'Ascenzo (Cardiologist, A.O.U. Città della Salute e della Scienza) — Principal investigator
First posted
May 7, 2021
Start date
Feb 1, 2021
Primary completion
Jan 31, 2025
Completion
Sep 26, 2026
Last update
Sep 30, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion